Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL201 in Healthy Subjects
NCT04551534Phase 1Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Jun 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing DNL201 with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events up to 20 days, Maximum observed concentration up to 10 days and 5 more. Started Jun 2017; status: completed.
02
Drugs
DNL201
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04551534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551534.